| Autor: |
J S, Lambert, L M, Mofenson, C V, Fletcher, J, Moye, E R, Stiehm, W A, Meyer, G J, Nemo, B J, Mathieson, G, Hirsch, C V, Sapan, L M, Cummins, E, Jimenez, E, O'Neill, A, Kovacs, A, Stek |
| Rok vydání: |
1997 |
| Předmět: |
|
| Zdroj: |
The Journal of infectious diseases. 175(2) |
| ISSN: |
0022-1899 |
| Popis: |
The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intravenous immunoglobulin (HIVIG) were evaluated in the first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis. Using 200 mg/kg, mean half-life and volume of distribution (Vd) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance. Transplacental passage occurred. Newborn single-dose half-life, Vd, and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively. HIVIG rapidly cleared maternal serum immune complex-dissociated p24 antigen, and plasma HIV-1 RNA levels were stable. Mild to moderate adverse clinical effects occurred in 2 of 103 maternal and 2 of 25 infant infusions. No adverse hematologic, blood chemistry, or immunologic effects were seen. HIVIG is well-tolerated in HIV-infected pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmacokinetics similar to those of other immunoglobulin preparations. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
